ArticleImmunologic research2026
Current and projected trends in rheumatoid arthritis among postmenopausal women in the U.S.: a population-based analysis of the Global Burden of Disease Study 2021, with projections to 2035.
Article in Immunologic research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Extracellular vesicle-mediated immunomodulation and targeted delivery: breakthroughs and challenges in rheumatoid arthritis therapy.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Rheumatoid arthritis (RA) is a chronic autoimmune inflammatory disorder with a high prevalence among postmenopausal women (PMW), and it is associated with substantial functional impairment and reduced quality of life. To inform targeted prevention strategies for high-risk populations in the U.S., a comprehensive and up-to-date assessment of disease burden in this population is needed. We conducted a quantitative analysis of the prevalence, years lived with disability (YLDs), and disability-adjusted life years (DALYs) of RA among PMW (PMWRA) in the U.S. from 1990 to 2021. In addition, disease trends were projected for 2022-2035 using data from the Global Burden of Disease Study (GBD) 2021. We extracted state-level estimates of prevalence, YLDs, and DALYs for PMWRA across 51 U.S. states from 1990 to 2021. Temporal trends were summarized using the average annual percent change (AAPC), and geographic and age-specific differences were assessed. Major risk factors contributing to state- and age-specific YLDs and DALYs were analyzed. Future projections were forecast using autoregressive integrated moving average (ARIMA) and exponential smoothing state-space (ETS) models. All analyses were conducted using R version 4.4.2 and the Joinpoint Regression Program. From 1990 to 2021, prevalence, YLD, and DALY rates among U.S. PMWRA showed upward trends, with AAPCs of 0.55, 0.50, and 0.04, respectively; the corresponding total percent changes in numbers were 1.13, 1.10, and 0.82. In 2021, Montana exhibited the highest prevalence (2,235.76), YLD (277.29), and DALY rates (362.62) among all states nationwide. The disease burden increased with the rising sociodemographic index up to a threshold and then declined. Age-stratified analyses indicated increasing prevalence, YLD, and DALY rates across nearly all age groups. Smoking emerged as the principal risk factor for PMWRA-related YLDs and DALYs across ages and regions. Forecasts based on ARIMA and ETS models indicated continued increases in prevalence and YLDs, whereas DALY rates were projected to decline. The burden of PMWRA among U.S. women is projected to continue rising, with concentration in specific states and age groups, which emphasizes the need for targeted public-health interventions to mitigate the burden in this population.
Indexed as
Identifiers
41518472What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.